Followers | 2 |
Posts | 108 |
Boards Moderated | 0 |
Alias Born | 07/06/2020 |
Monday, May 06, 2024 8:04:27 AM
Recent CVKD News
- Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024 • PR Newswire (US) • 05/23/2024 01:00:00 PM
- Cadrenal Therapeutics Provides First Quarter 2024 Corporate Update • PR Newswire (US) • 05/09/2024 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 10:23:10 AM
- Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024 • PR Newswire (US) • 04/11/2024 08:30:00 PM
- Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts • PR Newswire (US) • 04/09/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2024 01:15:09 PM
- Cadrenal Therapeutics Provides Fourth Quarter 2023 Corporate Update • PR Newswire (US) • 03/11/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2024 10:24:44 PM
- Cadrenal Therapeutics to Participate at Technology and Heart Failure Therapeutics (THT) Conference • PR Newswire (US) • 02/26/2024 02:00:00 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 02/15/2024 01:00:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/12/2024 09:49:23 PM
- Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal Trial • PR Newswire (US) • 02/08/2024 02:00:00 PM
- Cadrenal Therapeutics Highlights Publication of Peer-Reviewed Article Supporting Need for New Anticoagulation Therapy for Patients with Certain Medical Conditions • PR Newswire (US) • 01/31/2024 02:00:00 PM
- Cadrenal Therapeutics to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024 • PR Newswire (US) • 01/24/2024 02:00:00 PM
- Cadrenal Therapeutics to Present at the Biotech Showcase on January 8, 2024 Alongside the J.P. Morgan Annual Healthcare Conference • PR Newswire (US) • 01/04/2024 02:00:00 PM
- Noble Capital Markets Initiates Coverage on Cadrenal Therapeutics with Outperform Rating and US$4.00 Price Target • PR Newswire (US) • 12/19/2023 02:00:00 PM
- Cadrenal Therapeutics Engages The Sage Group to Advance Tecarfarin's Late-Stage Development and Commercialization • PR Newswire (US) • 12/12/2023 02:00:00 PM
- Cadrenal Therapeutics to Present at the NobleCon 19 Conference on December 4, 2023 • PR Newswire (US) • 11/30/2023 09:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 02:15:30 PM
- Cadrenal Therapeutics Provides Third Quarter 2023 Corporate Update • PR Newswire (US) • 11/09/2023 02:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 01:00:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/23/2023 09:04:39 PM
- Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2023 Investor Conference • PR Newswire (US) • 10/09/2023 08:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/08/2023 08:10:34 PM
- Cadrenal Therapeutics Highlights Additional Need for a New Vitamin K Antagonist (Tecarfarin) Following Updates from the Recent European Society of Cardiology Congress • PR Newswire (US) • 09/05/2023 12:00:00 PM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM